Altered molecular pathways and prognostic markers in active systemic juvenile idiopathic arthritis: integrated bioinformatic analysis.
Journal
Bosnian journal of basic medical sciences
ISSN: 1840-4812
Titre abrégé: Bosn J Basic Med Sci
Pays: Bosnia and Herzegovina
ID NLM: 101200947
Informations de publication
Date de publication:
01 Apr 2022
01 Apr 2022
Historique:
received:
08
05
2021
accepted:
07
08
2021
pubmed:
5
9
2021
medline:
6
4
2022
entrez:
4
9
2021
Statut:
epublish
Résumé
Systemic juvenile idiopathic arthritis (SJIA) is a severe childhood-onset inflammatory disease characterized by arthritis accompanied by systemic auto-inflammation and extra-articular symptoms. While recent advances have unraveled a range of risk factors, the pathomechanisms involved in SJIA and potential prognostic markers for treatment success remain partly unknown. In this study, we included 70 active SJIA and 55 healthy control patients from the National Center for Biotechnology Information to analyze for differentially expressed genes (DEGs) using R. Functional enrichment analysis, protein-protein interaction (PPI), and gene module construction were performed for DEGs and hub gene set. We additionally examined immune system cell composition with CIBERSORT and predicted prognostic markers and potential treatment drugs for SJIA. In total, 94 upregulated and 24 downregulated DEGs were identified. Two specific modules of interest and eight hub genes (ARG1, DEFA4, HP, MMP8, MMP9, MPO, OLFM4, PGLYRP1) were screened out. Functional enrichment analysis suggested that complex neutrophil-related functions play a decisive role in the disease pathogenesis. CIBERSORT indicated neutrophils, M0 macrophages, CD8+ T cells, and naïve B cells to be relevant drivers of disease progression. Additionally, we identified TPM2 and GZMB as potential prognostic markers for treatment response to canakinumab. Moreover, sulindac sulfide, (-)-catechin, and phenanthridinone were identified as promising treatment agents. This study provides a new insight into molecular and cellular pathogenesis of active SJIA and highlights potential targets for further research.
Identifiants
pubmed: 34480465
doi: 10.17305/bjbms.2021.6016
pmc: PMC8977090
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-260Références
Inflamm Res. 2001 Nov;50(11):561-9
pubmed: 11766996
Clin Proteomics. 2010 Dec;6(4):175-193
pubmed: 21124648
Am J Respir Crit Care Med. 2002 Feb 1;165(3):372-7
pubmed: 11818323
Baillieres Clin Rheumatol. 1998 May;12(2):245-71
pubmed: 9890097
Arthritis Res Ther. 2015 Jul 16;17:180
pubmed: 26179062
Nat Rev Immunol. 2011 Jul 25;11(8):519-31
pubmed: 21785456
Ann Rheum Dis. 2009 Feb;68(2):264-72
pubmed: 18388159
Mol Med Rep. 2018 Oct;18(4):3737-3743
pubmed: 30132542
Cytokine. 2021 Feb;138:155397
pubmed: 33341002
Front Immunol. 2020 Nov 05;11:583513
pubmed: 33224145
J Rheumatol. 2004 Feb;31(2):390-2
pubmed: 14760812
Arch Biochem Biophys. 2018 Feb 15;640:47-52
pubmed: 29336940
Arthritis Res Ther. 2017 Jan 23;19(1):13
pubmed: 28115015
Ann Rheum Dis. 2017 May;76(5):906-913
pubmed: 27927641
J Clin Gastroenterol. 1994 Jan;18(1):84-5
pubmed: 8113593
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Arthritis Rheum. 2007 Nov;56(11):3793-804
pubmed: 17968951
Immunology. 2014 Jun;142(2):227-36
pubmed: 24405357
Front Immunol. 2018 Dec 18;9:2995
pubmed: 30619348
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1987 Nov;20(4):279-89
pubmed: 3449318
Drug Des Devel Ther. 2018 Jun 08;12:1633-1643
pubmed: 29922038
Adv Ther. 2007 May-Jun;24(3):679-90
pubmed: 17660179
Arthritis Rheum. 2008 May;58(5):1505-15
pubmed: 18438814
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Rheumatology (Oxford). 2018 Mar 1;57(3):488-498
pubmed: 29240923
Arch Dis Child. 2017 Feb;102(2):206-207
pubmed: 27799155
Mol Immunol. 2016 Sep;77:205-12
pubmed: 27541693
J Leukoc Biol. 2016 Jul;100(1):213-22
pubmed: 27034404
Expert Rev Clin Immunol. 2015 May;11(5):575-88
pubmed: 25843554
Bioinformatics. 2014 Oct;30(19):2757-63
pubmed: 24907368
Arthritis Rheumatol. 2018 Jun;70(6):943-956
pubmed: 29426067
Oncogene. 2017 Aug 10;36(32):4597-4609
pubmed: 28368394
J Clin Invest. 2013 Apr;123(4):1580-9
pubmed: 23454751
World J Pediatr. 2020 Oct;16(5):502-513
pubmed: 31641939
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
J Rheumatol. 2007 May;34(5):1133-8
pubmed: 17343315
Adv Healthc Mater. 2017 Jul;6(13):
pubmed: 28557249
Ann Rheum Dis. 2011 May;70(5):747-54
pubmed: 21173013
Mol Med Rep. 2019 Jan;19(1):589-594
pubmed: 30431075
Arthritis Res Ther. 2011 Apr 26;13(2):R69
pubmed: 21521520
CPT Pharmacometrics Syst Pharmacol. 2013 Oct 16;2:e79
pubmed: 24132163
Arthritis Rheum. 1997 Jul;40(7):1202-9
pubmed: 9214419
Free Radic Biol Med. 2003 Nov 1;35(9):1008-17
pubmed: 14572604
Genome Med. 2018 Jun 27;10(1):48
pubmed: 29950172
J Immunother Cancer. 2019 Feb 6;7(1):32
pubmed: 30728077
Biomed Res Int. 2019 Oct 28;2019:7420345
pubmed: 31781639
Clin Chim Acta. 2003 Feb;328(1-2):105-11
pubmed: 12559605
Redox Rep. 2001;6(6):386-8
pubmed: 11865982
Biomolecules. 2020 Sep 04;10(9):
pubmed: 32899743
Eur J Pharmacol. 2001 Apr 6;417(1-2):37-43
pubmed: 11301057
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15970-5
pubmed: 26598658
Blood. 2016 May 5;127(18):2173-81
pubmed: 27002116
J Leukoc Biol. 2015 Jan;97(1):181-9
pubmed: 25387833
Blood. 2010 Feb 11;115(6):1156-65
pubmed: 19965634